Study Reveals Wegovy Yields Greater Weight Loss in Women with Heart Failure

Research shows women with HFpEF lose more weight than men on Novo Nordisk's obesity drug, though heart benefits are similar.

Novo Nordisk's Wegovy led to 9.6% weight loss in women with HFpEF, compared to 7.2% in men.
Both sexes saw similar improvements in heart failure symptoms despite the weight loss disparity.
The study involved 1,145 participants and was presented at the American Diabetes Association's meeting.
HFpEF accounts for about half of heart failure cases and is especially common among overweight women.
Further research is needed to understand why greater weight loss in women does not translate to better heart outcomes.